[go: up one dir, main page]

US20100081695A1 - 2-N-{5-[ [4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate - Google Patents

2-N-{5-[ [4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate Download PDF

Info

Publication number
US20100081695A1
US20100081695A1 US12/592,442 US59244209A US2010081695A1 US 20100081695 A1 US20100081695 A1 US 20100081695A1 US 59244209 A US59244209 A US 59244209A US 2010081695 A1 US2010081695 A1 US 2010081695A1
Authority
US
United States
Prior art keywords
compound
rosiglitazone maleate
pharmaceutical composition
methyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/592,442
Inventor
Yehudit Dolitzky
Yoseph Avezov
Dina Spivak
Minutza Leibovici
Ben-Zion Solomon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Priority to US12/592,442 priority Critical patent/US20100081695A1/en
Publication of US20100081695A1 publication Critical patent/US20100081695A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to a rosiglitazone maleate impurity and its use as a reference marker and reference standard.
  • Rosiglitazone is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity.
  • Chemically, rosiglitazone maleate is ( ⁇ )-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, (Z)-2-butenedioate (1:1) with a molecular weight of 473.52 (357.44 free base).
  • the molecule has a single chiral center and is present as a racemate. Due to rapid interconversion, the enantiomers are functionally indistinguishable. (Physicians' Desk Reference (electronic version), Thomson Micromedex, Greenwood Village, Colo. (Edition expires [December 2005])).
  • Rosiglitazone Maleate is marketed in the United States under the trade name AVANDIA® in 2 mg, 4 mg, and 8 mg tablets.
  • Rosiglitazone Maleate in combination with Metformin HCl under the trade name AVANDAMET® in tablets with the following dosages: 1 mg/500 mg; 2 mg/500 mg; 4 mg/500 mg; 2 mg/1000 mg; 4 mg/1000 mg.
  • Rosiglitazone and its maleate salt are disclosed in the following United States patents, hereby incorporated by reference: U.S. Pat. Nos. 5,002,953; 5,741,803; 6,288,095.
  • the regulatory agencies generally require a manufacturing specification that sets the maximum amount of each identified impurity as well as the maximum amount for all remaining unidentified impurities.
  • stability testing is performed on the pharmaceutical composition to insure that it does not substantially change over time.
  • Described herein is an impurity associated with rosiglitazone maleate, along with methods and formulations for minimizing the impurity.
  • the subject invention provides an isolated compound of the formula:
  • the subject invention also provides a composition comprising a compound of the formula:
  • composition is free of rosiglitazone maleate.
  • the subject invention also provides a composition comprising a compound having the formula (I):
  • composition in an amount of at least 0.2% based on the weight of the composition, and a carrier.
  • the subject invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a granulate of a mixture of:
  • the subject invention also provides a sealed package comprising:
  • the subject invention also provides a process for preparing a pharmaceutical composition comprising rosiglitazone maleate and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition comprises less than 1.2% of 2-N- ⁇ 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione ⁇ -butanedioic acid, based on the combined weight of 2-N- ⁇ 5-[([4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione ⁇ -butanedioic acid and rosiglitazone maleate,
  • the subject invention also provides a process for validating a batch of a pharmaceutical composition containing rosiglitazone maleate and at least one pharmaceutically acceptable carrier for distribution comprising:
  • the chemical name of this compound is: 2-N- ⁇ 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione ⁇ -butanedioic acid.
  • the subject invention provides a isolated compound of the formula:
  • the subject invention also provides a composition comprising a compound of the formula:
  • composition is free of rosiglitazone maleate.
  • the subject invention also provides a composition comprising a compound having the formula (I):
  • composition in an amount of at least 0.2% based on the weight of the composition, and a carrier.
  • the composition comprises at least 1.5% of the compound of the formula (I), based on the weight of the composition.
  • the composition comprises at least 50% of the compound of the formula (I), based on the weight of the composition.
  • the composition comprises from more than 0 to 99.8% by weight of rosiglitazone maleate, based on the combined weight of the compound of the formula (I) and the rosiglitazone maleate.
  • the composition comprises from more than 0 to 98.5% by weight of rosiglitazone maleate, based on the combined weight of the compound of the formula (I) and the rosiglitazone maleate.
  • composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier.
  • the compound of formula (I) is present in an amount between 0.20% and 5.0% based on the combined weight of the compound of formula (I) and rosiglitazone maleate in the composition.
  • 0.20% to 5.0% it is meant that all hundredth, tenth and integer unit amounts within the range are specifically disclosed as part of the invention. Thus, 0.25%, 0.30%, 0.35% . . . 4.95% unit amounts are included as embodiments of this invention.
  • the compound of formula (I) is present in an amount between 0.20% and 3.0% based on the combined weight of the compound of formula (I) and rosiglitazone maleate in the composition.
  • 0.20% to 3.0% it is meant that all hundredth, tenth and integer unit amounts within the range are specifically disclosed as part of the invention. Thus, 0.25%, 0.30%, 0.35% . . . 2.95% unit amounts are included as embodiments of this invention.
  • the compound of formula (I) is present in an amount between 0.25% and 2.0% based on the combined weight of the compound of formula (I) and rosiglitazone maleate in the composition.
  • 0.25% to 2.0% it is meant that all hundredth, tenth and integer unit amounts within the range are specifically disclosed as part of the invention.
  • 0.30%, 0.35%, 0.40% . . . 1.95% unit amounts are included as embodiments of this invention.
  • the compound of formula (I) is present in an amount between 0.70% and 2.0% based on the combined weight of the compound of formula (I) and rosiglitazone maleate in the composition.
  • 0.70% to 2.0% it is meant that all hundredth, tenth and integer unit amounts within the range are specifically disclosed as part of the invention. Thus, 0.75%, 0.80%, 0.85% . . . 1.95% unit amounts are included as embodiments of this invention.
  • the compound of formula (I) is present in an amount between 1.10% and 2.0% based on the combined weight of the compound of formula (I) and rosiglitazone maleate in the composition.
  • 1.10% to 2.0% it is meant that all hundredth, tenth and integer unit amounts within the range are specifically disclosed as part of the invention.
  • 1.15%, 1.20%, 1.25% . . . 1.95% unit amounts are included as embodiments of this invention.
  • the subject invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a granulate of a mixture of:
  • the compound of formula (I) is present in an amount less than 0.1% based on the combined weight of the compound and rosiglitazone maleate.
  • the granulate is a product of wet granulation in an aqueous solution.
  • the granulate is a milled granulate.
  • the pharmaceutical composition further comprises at least one disintegrant and at least one binder.
  • the disintegrant is croscarmellose sodium
  • the binder is povidone
  • the pharmaceutical composition further comprises a biguanide antidiabetic compound.
  • the biguanide antidiabetic compound is a pharmaceutically acceptable salt of metformin.
  • the pharmaceutically acceptable salt of metformin is metformin hydrochloride.
  • the pharmaceutical composition further comprises a sulfonyl urea antidiabetic compound.
  • the sulfonyl urea antidiabetic compound is glimepride or glipizide.
  • the pharmaceutical composition is in the form of a tablet.
  • the tablet comprises a tablet core, the tablet core comprising, by weight, between 1% and 4% rosiglitazone maleate, 6% croscarmellose sodium, 2% povidone, between 0.5% and 1% magnesium stearate and between 87% and 90% filler, the filler consisting of lactose and microcrystalline cellulose.
  • the tablet comprises a tablet core, the tablet core comprising, by weight, between 75% and 76% metformin HCl, between 0.2% and 1% rosiglitazone maleate, between 5% and 6% povidone, between 1% and 2% croscarmellose sodium, between 4% and 5% starch, and between 0.5% and 1% magnesium stearate.
  • the subject invention also provides a sealed package comprising the composition described herein or the pharmaceutical composition described herein.
  • the sealed package further comprises a desiccant.
  • the desiccant is silica gel.
  • the sealed package is a HDPE bottle.
  • the sealed package comprises the pharmaceutical composition described herein, wherein the pharmaceutical composition contains less than 1.0% of a compound of the formula (I):
  • the subject invention also provides a sealed package comprising:
  • the pharmaceutical composition further comprises a compound of the formula (I):
  • the pharmaceutical composition contains less than 1.0% of a compound of the formula (I):
  • the pharmaceutical composition further comprises at least one disintegrant and at least one binder.
  • the disintegrant is croscarmellose sodium
  • the binder is povidone
  • the pharmaceutical composition further comprises a biguanide antidiabetic compound.
  • the biguanide antidiabetic compound is a pharmaceutically acceptable salt of metformin.
  • the pharmaceutically acceptable salt of metformin is metformin HCl.
  • the pharmaceutical composition further comprises a sulfonyl urea antidiabetic compound.
  • the sulfonyl urea antidiabetic compound is glimepride or glipizide.
  • the pharmaceutical composition is in the form of a tablet.
  • the tablet comprises a tablet core, the tablet core comprising, by weight, between 1% and 4% rosiglitazone maleate, 6% croscarmellose sodium, 2% povidone, between 0.5% and 1% magnesium stearate and between 87% and 90% filler, the filler consisting of lactose and microcrystalline cellulose.
  • the tablet comprises a tablet core, the tablet core comprising, by weight, between 75% and 76% metformin HCl, between 0.2% and 1% rosiglitazone maleate, between 5% and 6% povidone, between 1% and 2% croscarmellose sodium, between 4% and 5% starch, and between 0.5% and 1% magnesium stearate.
  • the desiccant is silica gel.
  • the pharmaceutical composition is prepared by wet granulation with water.
  • the sealed package is a HDPE bottle.
  • the subject invention also provides a process for making the pharmaceutical composition described herein, comprising
  • steps c)-e) are performed in an atmosphere having a relative humidity of 30% or less.
  • the subject invention also provides another process for making the pharmaceutical composition described herein, comprising
  • steps c)-f) are performed in an atmosphere having a relative humidity of 30% or less.
  • the process further comprises coating the tablet core with a film coating.
  • the subject invention also provides another process for preparing the pharmaceutical composition described herein or the sealed package described herein, comprising:
  • the pharmaceutical composition is prepared by wet granulation in an aqueous solution.
  • the subject invention also provides process for preparing a pharmaceutical composition comprising rosiglitazone maleate and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition comprises less than 1.2% of 2-N- ⁇ 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione ⁇ -butanedioic acid, based on the combined weight of 2-N- ⁇ 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione ⁇ -butanedioic acid and rosiglitazone maleate,
  • the pharmaceutical composition is prepared by wet granulation in an aqueous solution.
  • the subject invention also provides a process for validating a batch of a pharmaceutical composition containing rosiglitazone maleate and at least one pharmaceutically acceptable carrier for distribution comprising:
  • the batch is validated for distribution only if the sample of the batch is determined in step a) to contain less than 1.0% by weight of 2-N- ⁇ 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione ⁇ -butanedioic acid.
  • the batch is validated for distribution only if the sample of the batch is determined in step a) to contain less than 0.5% by weight of 2-N- ⁇ 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione ⁇ -butanedioic acid.
  • the subject invention also provides a process for making the isolated compound described herein, comprising:
  • the compound is isolated from the mixture via chromatography.
  • the compound is isolated from the mixture via recrystallization.
  • the subject invention also provides a method for increasing insulin sensitivity in a human subject comprising administering to the human subject the pharmaceutical composition described herein.
  • the subject invention also provides use of the composition described herein or the pharmaceutical composition described herein for manufacturing a medicament for increasing insulin sensitivity in a human subject.
  • the subject invention also provides a the pharmaceutical composition described herein for increasing insulin sensitivity in a human subject.
  • drug substance refers to the active ingredient in a drug product, which provides pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man or animals.
  • drug product or “DP” refers to the finished dosage form containing the drug substance as well as at least one pharmaceutically acceptable carrier.
  • a “sealed” package, container or coating substantially prevents the atmosphere from coming in contact with the contents of the package or container or with the material coated by the coating.
  • HDPE high density polyethylene plastic
  • Impurities can be present in the active pharmaceutical ingredient (API) or in the pharmaceutical dosage form, for example, in tablets.
  • API active pharmaceutical ingredient
  • the excipients in the dosage form cause the degradation of rosiglitazone maleate and thereby bring about the presence of impurities. It is possible that these impurities only come into being after time and are found as a result of long term or accelerated stability studies.
  • impurities are defined spectroscopically and or with another physical method, and then associated with a peak position, such as that in a chromatogram or a spot on a TLC plate.
  • a peak position such as that in a chromatogram or a spot on a TLC plate.
  • the retention time can vary based upon the condition of the instrumentation, as well as many other factors. To mitigate the effects such variations have upon accurate identification of an impurity, practitioners use the “Relative retention time,” (RRT) to identify impurities. (Strobel p. 922)
  • RRT Relative retention time
  • the RRT of an impurity is defined as the retention time of the impurity divided by the retention time of a reference marker. It may be advantageous to select a compound other than the API that is added to the mixture in an amount sufficiently large to be detectable and sufficiently low as not to saturate the column and to use that compound as the reference marker for determination of the RRT.
  • a reference standard is a compound in a relatively pure state, used to quantify the amount of the compound in an unknown mixture.
  • a reference standard can be used as either an external standard or as an internal standard.
  • An external standard is employed when a solution of a known concentration of the reference standard and an unknown mixture are analyzed using the same technique.
  • the amount of the compound in the mixture can be determined by comparing the magnitude of the detector responses.
  • An internal standard is employed when an unknown mixture contains a detectable amount of the reference standard compound without addition of the reference standard.
  • the amount of internal standard is determined by preparing at least two samples by adding known and differing amounts of the internal standard.
  • the proportion of the detector response due to the reference standard present in the mixture can be determined by plotting the detector response attained for each of the samples against the amount of the reference standard added to each of the samples and extrapolating the plot to zero.
  • compositions may be prepared as medicaments to be administered orally, parenterally, rectally or transdermally.
  • suitable forms for oral administration include tablets, compressed or coated pills, dragees, sachets, hard or soft gelatin capsules, sublingual tablets, syrups and suspensions; for parenteral administration the invention provides ampoules or vials that include an aqueous or non-aqueous solution or emulsion; for rectal administration there are provided suppositories with hydrophilic or hydrophobic vehicles; and for topical application as ointments and transdermal delivery there are provided suitable delivery systems as known in the art.
  • Tablets may contain suitable binders, lubricants, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents.
  • the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, gelatin, agar, starch, sucrose, glucose, methyl cellulose, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, microcrystalline cellulose and the like.
  • Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn starch, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, povidone, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, sodium benzoate, sodium acetate, sodium chloride, stearic acid, sodium stearyl fumarate, talc and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, croscarmellose sodium, sodium starch glycolate and the like.
  • rosiglitazone maleate 1 g was mixed with 1 g of water in a reaction vessel with screw cap. The mixture was kept at 70° C. for 5 days. To this mixture, 24 mL of methanol: water solution of trifluoroacetic acid (with a pH of about 2.8) (3:2) were added. The rosiglitazone base concentration of the solution was 40 mg/mL.
  • rosiglitazone maleate was mixed with 1.3 g of water in a reaction vessel with screw cap. The mixture was kept at 70° C. for 5 days. 4 ml of methanol: water solution of trifluoroacetic acid with a pH of about 2.8 (3:2) were added to the mixture.
  • the sample was stored at 2-8° C. for 5 days. Crystals of rosiglitazone maleate enriched with Compound 1 precipitated spontaneously from the sample. These crystals were vacuum-filtered and washed with cold water and methanol. These crude crystals were then dissolved in hot isopropyl alcohol and cooled in an ice bath until crystals of Compound 1 appeared. The crystals were vacuum-filtered then washed with cold isopropyl alcohol, methanol and dried to yield 40 mg. Purity: about 97-98%.
  • Rosiglitazone maleate analytical standard was dissolved in diluent to make a solution with a concentration of approximately 0.2 ⁇ g/mL in terms of rosiglitazone.
  • the standard and samples were injected and the peak due to Compound 1 was monitored and calculated in the relevant sample.
  • the peak which corresponded to Compound 1 was found to elute at approximately a Relative Retention Time of 0.7, when compared to the rosiglitazone maleate peak.
  • Solution A 20 mM sodium dihydrogen phosphate and 10 mM sodium pentanesulfonate solution at pH 2.8.
  • Solution B 75% Solution A and 25% acetonitrile.
  • Rosiglitazone maleate analytical standard was diluted with diluent to a concentration of 0.1 ⁇ g/mL.
  • Tablets were dissolved and diluted based on the declared strengths.
  • the quantifiable limit of this method was determined to be 0.1% based on the combined weight of Compound 1 and rosiglitazone.
  • Metformin HCl & Povidone (PVP K-30) of Part I were transferred to a high shear mixer and mixed.
  • Microcrystalline cellulose and Colloidal Silicon Dioxide of part II were screened and mixed in a Y-cone mixer with Rosiglitazone and Microcrystalline cellulose of Part III and with Microcrystalline cellulose of part IV.
  • the mixture from Step 2 was transferred to the high shear mixer from Step 1 and mixed.
  • Povidone (PVP K-90) solution in hot purified water was added to the high shear mixer from Step 3 & was mixed to attain a wet granulate. 5.
  • the granulate from Step 4 was dried in a Fluid Bed Dryer.
  • Steps 6 to 10 which follow were performed in an atmosphere with lower than 30% relative humidity.
  • the dried granulate was milled and transferred to a Flow bin or Y-cone.
  • Components of part V were screened through a sieve, transferred to Flow bin or Y-Cone from Step 6, and mixed.
  • Magnesium stearate was screened through a sieve, transferred to Flow bin or Y-cone from Step 7, and mixed to get the final blend.
  • the final blend from Step 8 was compressed into cores in a tableting machine to yield tablet cores of the appropriate dosages.
  • the cores were coated using OPADRY®, which consists of HPMC2910/HYPROMELLOSE 6 cP, Titanium dioxide, Macrogol/PEG 400, Iron Oxide yellow/iron oxide red; using a coating machine.
  • Part I The components of Part I were transferred to a high shear mixer and mixed. 2. Purified water (granulation solution) was added to the high shear mixer from Step 1 and mixed, and a wet granulate was attained. 3. The granulate from Step 2 was dried in a Fluid Bed Dryer.
  • Steps 4 to 7 which follow were performed in an atmosphere with lower than 30% relative humidity.
  • the dried granulate was milled and transferred to a flow bin or Y-cone and mixed. 5.
  • Magnesium stearate was screened through a sieve, transferred to the flow bin or Y-cone from Step 4 and mixed to attain the final blend. 6.
  • the final blend from Step 5 was compressed in to cores in a tableting machine. 7.
  • the cores were coated in a coating machine using Opadry® which consists of: HPMC2910/HYPROMELLOSE 6 cP, Titanium dioxide, Macrogol/PEG 3350, Triacetin/Glycerol, Triacetate, Talc, Iron Oxide yellow/red/black, FD&C Blue#2/Indigo Carmine Aluminum Lake.
  • drug product 500 mg metformin/4 mg rosiglitazone base
  • Example 5a drug product prepared as in Example 5a made from two different batches of the rosiglitazone maleate drug substance was analyzed for presence of Compound 1 before and after thermodegradation using the method described in Example 4.
  • thermodegradation was performed by subjecting the samples to 65° C. heat and 100% relative humidity for 5 days.
  • the content of Compound 1 is listed in the table below.
  • the peaks were measured and the area percent (area of Compound 1 peak/area of all rosiglitazone related peaks) of the Compound 1 peak is listed below.
  • Rosiglitazone maleate was mixed with various excipients and with metformin in the same proportions as present in the 500 mg/4 mg (base strength) metformin/rosiglitazone maleate tablets. 0.5 ml of water was added to each mixture, and the samples were kept at 65° C. for 4 days. The amount of Compound 1 was determined in each of the samples using the method in Example 4. The results are summarized in the table below. The peaks were measured and the area percent (area of Compound 1 peak/area of all rosiglitazone related peaks) of the Compound 1 peak is listed below.
  • Placebo mix A refers to a mixture of excipients as indicated in Example 5a, with the exception of rosiglitazone maleate.
  • Placebo mix B refers to a mixture of excipients as indicated in Example 5b, with the exception of rosiglitazone maleate.
  • This Example indicates that the presence of moisture and some excipients, especially starch, enhances the production of Compound 1 in accelerated conditions.
  • Tablets were prepared as described in Example 5. 100 tablets were packed into high density polyethylene (HDPE) bottles either with or without silica gel and were stored at 75% RH and 40° C. for 3 months. The tablets were then tested for Compound 1. The results, in terms of percentage of Compound 1 are listed in the table below. The percentage of compound in all of the dosages in the table below before the stability testing was less than 0.1%.
  • HDPE high density polyethylene
  • Example 4 The amount of Compound 1 in commercially available AVANDAMET® tablets 1000/2 mg was analyzed using Example 4. Compound 1 was present in an amount that was less than quantifiable.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed is an isolated compound of the formula:
Figure US20100081695A1-20100401-C00001
along with methods of detecting it and of minimizing it in improved pharmaceutical compositions of rosiglitazone maleate.

Description

  • Throughout this application various publications, published patent applications, and patents are referenced. The disclosures of these documents in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
    • FIELD OF THE INVENTION
  • The present invention relates to a rosiglitazone maleate impurity and its use as a reference marker and reference standard.
    • BACKGROUND OF THE INVENTION
  • Rosiglitazone is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. Chemically, rosiglitazone maleate is (±)-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, (Z)-2-butenedioate (1:1) with a molecular weight of 473.52 (357.44 free base). The molecule has a single chiral center and is present as a racemate. Due to rapid interconversion, the enantiomers are functionally indistinguishable. (Physicians' Desk Reference (electronic version), Thomson Micromedex, Greenwood Village, Colo. (Edition expires [December 2005])).
  • The structural formula of Rosiglitazone Maleate is:
  • Figure US20100081695A1-20100401-C00002
  • Rosiglitazone Maleate is marketed in the United States under the trade name AVANDIA® in 2 mg, 4 mg, and 8 mg tablets. In addition, Rosiglitazone Maleate in combination with Metformin HCl under the trade name AVANDAMET® in tablets with the following dosages: 1 mg/500 mg; 2 mg/500 mg; 4 mg/500 mg; 2 mg/1000 mg; 4 mg/1000 mg.
  • Rosiglitazone and its maleate salt are disclosed in the following United States patents, hereby incorporated by reference: U.S. Pat. Nos. 5,002,953; 5,741,803; 6,288,095.
  • Pharmaceutical products are regulated in most countries by governmental agencies. For example, the U.S. Food & Drug Administration (FDA) generally requires an applicant to show safety and efficacy of the pharmaceutical product during the approval/review phase and requires monitoring of the safety of the drug post-approval.
  • In order to satisfy safety concerns, the regulatory agencies generally require a manufacturing specification that sets the maximum amount of each identified impurity as well as the maximum amount for all remaining unidentified impurities. In addition, stability testing is performed on the pharmaceutical composition to insure that it does not substantially change over time.
  • Described herein is an impurity associated with rosiglitazone maleate, along with methods and formulations for minimizing the impurity.
    • SUMMARY OF THE INVENTION
  • The subject invention provides an isolated compound of the formula:
  • Figure US20100081695A1-20100401-C00003
  • The subject invention also provides a composition comprising a compound of the formula:
  • Figure US20100081695A1-20100401-C00004
  • wherein the composition is free of rosiglitazone maleate.
  • The subject invention also provides a composition comprising a compound having the formula (I):
  • Figure US20100081695A1-20100401-C00005
  • in an amount of at least 0.2% based on the weight of the composition, and a carrier.
  • The subject invention also provides a pharmaceutical composition comprising a granulate of a mixture of:
      • a) rosiglitazone maleate;
      • b) at least one pharmaceutically acceptable carrier; and
      • c) less than 0.1% of the compound of the formula (I):
  • Figure US20100081695A1-20100401-C00006
      • based on the combined weight of the compound of the formula (I) and rosiglitazone maleate.
  • The subject invention also provides a sealed package comprising:
      • a pharmaceutical composition comprising rosiglitazone maleate and at least one pharmaceutically acceptable carrier; and
        • a desiccant.
  • The subject invention also provides a process for preparing a pharmaceutical composition comprising rosiglitazone maleate and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition comprises less than 1.2% of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid, based on the combined weight of 2-N-{5-[([4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid and rosiglitazone maleate,
      • comprising:
        • a. obtaining rosiglitazone maleate drug substance;
        • b. determining the total amount of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid present in the rosiglitazone maleate drug substance; and
        • c. including the rosiglitazone maleate drug substance in the preparation of the pharmaceutical composition only if the drug substance is determined to have less than 0.10% by weight of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid.
  • The subject invention also provides a process for validating a batch of a pharmaceutical composition containing rosiglitazone maleate and at least one pharmaceutically acceptable carrier for distribution comprising:
      • a. determining the total amount of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid in a sample of the batch after stability testing; and
      • b. validating the batch for distribution only if the sample of the batch is determined in step a) to contain less than 1.2% by weight of 2-N-{5-[([4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid.
    DETAILED DESCRIPTION OF THE INVENTION
  • This invention provides an isolated compound (Compound 1) of the following structural formula:
  • Figure US20100081695A1-20100401-C00007
  • The chemical name of this compound is: 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid.
  • The subject invention provides a isolated compound of the formula:
  • Figure US20100081695A1-20100401-C00008
  • The subject invention also provides a composition comprising a compound of the formula:
  • Figure US20100081695A1-20100401-C00009
  • wherein the composition is free of rosiglitazone maleate.
  • The subject invention also provides a composition comprising a compound having the formula (I):
  • Figure US20100081695A1-20100401-C00010
  • in an amount of at least 0.2% based on the weight of the composition, and a carrier.
  • In an embodiment, the composition comprises at least 1.5% of the compound of the formula (I), based on the weight of the composition.
  • In another embodiment, the composition comprises at least 50% of the compound of the formula (I), based on the weight of the composition.
  • In another embodiment, the composition comprises from more than 0 to 99.8% by weight of rosiglitazone maleate, based on the combined weight of the compound of the formula (I) and the rosiglitazone maleate.
  • In another embodiment, the composition comprises from more than 0 to 98.5% by weight of rosiglitazone maleate, based on the combined weight of the compound of the formula (I) and the rosiglitazone maleate.
  • In another embodiment, the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier.
  • In an embodiment of the pharmaceutical composition, the compound of formula (I) is present in an amount between 0.20% and 5.0% based on the combined weight of the compound of formula (I) and rosiglitazone maleate in the composition.
  • By 0.20% to 5.0% it is meant that all hundredth, tenth and integer unit amounts within the range are specifically disclosed as part of the invention. Thus, 0.25%, 0.30%, 0.35% . . . 4.95% unit amounts are included as embodiments of this invention.
  • In another embodiment of the pharmaceutical composition, the compound of formula (I) is present in an amount between 0.20% and 3.0% based on the combined weight of the compound of formula (I) and rosiglitazone maleate in the composition.
  • By 0.20% to 3.0% it is meant that all hundredth, tenth and integer unit amounts within the range are specifically disclosed as part of the invention. Thus, 0.25%, 0.30%, 0.35% . . . 2.95% unit amounts are included as embodiments of this invention.
  • In another embodiment of the pharmaceutical composition, the compound of formula (I) is present in an amount between 0.25% and 2.0% based on the combined weight of the compound of formula (I) and rosiglitazone maleate in the composition.
  • By 0.25% to 2.0% it is meant that all hundredth, tenth and integer unit amounts within the range are specifically disclosed as part of the invention. Thus, 0.30%, 0.35%, 0.40% . . . 1.95% unit amounts are included as embodiments of this invention.
  • In another embodiment of the pharmaceutical composition, the compound of formula (I) is present in an amount between 0.70% and 2.0% based on the combined weight of the compound of formula (I) and rosiglitazone maleate in the composition.
  • By 0.70% to 2.0% it is meant that all hundredth, tenth and integer unit amounts within the range are specifically disclosed as part of the invention. Thus, 0.75%, 0.80%, 0.85% . . . 1.95% unit amounts are included as embodiments of this invention.
  • In another embodiment of the pharmaceutical composition, the compound of formula (I) is present in an amount between 1.10% and 2.0% based on the combined weight of the compound of formula (I) and rosiglitazone maleate in the composition.
  • By 1.10% to 2.0% it is meant that all hundredth, tenth and integer unit amounts within the range are specifically disclosed as part of the invention. Thus, 1.15%, 1.20%, 1.25% . . . 1.95% unit amounts are included as embodiments of this invention.
  • The subject invention also provides a pharmaceutical composition comprising a granulate of a mixture of:
      • a) rosiglitazone maleate;
      • b) at least one pharmaceutically acceptable carrier; and
      • c) less than 0.1% of the compound of the formula (I):
  • Figure US20100081695A1-20100401-C00011
      • based on the combined weight of the compound of the formula (I) and rosiglitazone maleate.
  • In an embodiment of the pharmaceutical composition, the compound of formula (I) is present in an amount less than 0.1% based on the combined weight of the compound and rosiglitazone maleate.
  • In another embodiment of the pharmaceutical composition, the granulate is a product of wet granulation in an aqueous solution.
  • In another embodiment of the pharmaceutical composition, the granulate is a milled granulate.
  • In another embodiment, the pharmaceutical composition further comprises at least one disintegrant and at least one binder.
  • In another embodiment of the pharmaceutical composition, the disintegrant is croscarmellose sodium, and the binder is povidone.
  • In another embodiment, the pharmaceutical composition further comprises a biguanide antidiabetic compound.
  • In another embodiment of the pharmaceutical composition, the biguanide antidiabetic compound is a pharmaceutically acceptable salt of metformin.
  • In another embodiment of the pharmaceutical composition, the pharmaceutically acceptable salt of metformin is metformin hydrochloride.
  • In another embodiment, the pharmaceutical composition further comprises a sulfonyl urea antidiabetic compound.
  • In another embodiment of the pharmaceutical composition, the sulfonyl urea antidiabetic compound is glimepride or glipizide.
  • In another embodiment, the pharmaceutical composition is in the form of a tablet.
  • In another embodiment of the pharmaceutical composition, the tablet comprises a tablet core, the tablet core comprising, by weight, between 1% and 4% rosiglitazone maleate, 6% croscarmellose sodium, 2% povidone, between 0.5% and 1% magnesium stearate and between 87% and 90% filler, the filler consisting of lactose and microcrystalline cellulose.
  • In another embodiment of the pharmaceutical composition, the tablet comprises a tablet core, the tablet core comprising, by weight, between 75% and 76% metformin HCl, between 0.2% and 1% rosiglitazone maleate, between 5% and 6% povidone, between 1% and 2% croscarmellose sodium, between 4% and 5% starch, and between 0.5% and 1% magnesium stearate.
  • The subject invention also provides a sealed package comprising the composition described herein or the pharmaceutical composition described herein.
  • In an embodiment, the sealed package further comprises a desiccant.
  • In another embodiment of the sealed package, the desiccant is silica gel.
  • In another embodiment, the sealed package is a HDPE bottle.
  • In another embodiment of the sealed package, a net increase of the total content of a compound of the formula (I):
  • Figure US20100081695A1-20100401-C00012
      • based on the combined weight of the compound of the formula (I) and rosiglitazone maleate in the pharmaceutical composition, is 0.7% or less after storage of the sealed package at 75% relative humidity and 40° C. for 3 months.
  • In another embodiment, the sealed package comprises the pharmaceutical composition described herein, wherein the pharmaceutical composition contains less than 1.0% of a compound of the formula (I):
  • Figure US20100081695A1-20100401-C00013
      • based on the combined weight of the compound of the formula (I) and rosiglitazone maleate in the pharmaceutical composition, after storage of the sealed package at 75% relative humidity and 40° C. for 3 months.
  • The subject invention also provides a sealed package comprising:
      • a pharmaceutical composition comprising rosiglitazone maleate and at least one pharmaceutically acceptable carrier; and
        • a desiccant.
  • In an embodiment of the sealed package, the pharmaceutical composition further comprises a compound of the formula (I):
  • Figure US20100081695A1-20100401-C00014
      • in an amount of 1.0% or below, based on the combined weight of the compound of the formula (I) and rosiglitazone maleate in the pharmaceutical composition.
  • In another embodiment of the sealed package, the compound of the formula (I):
  • Figure US20100081695A1-20100401-C00015
      • is present in the pharmaceutical composition in an amount of less than 0.1%, based on the combined weight of the compound of the formula (I) and rosiglitazone maleate.
  • In another embodiment of the sealed package, the pharmaceutical composition contains less than 1.0% of a compound of the formula (I):
  • Figure US20100081695A1-20100401-C00016
      • based on the combined weight of the compound of the formula (I) and rosiglitazone maleate in the pharmaceutical composition, after storage of the sealed package at 75% relative humidity and 40° C. for 3 months.
  • In another embodiment of the sealed package, a net increase of the total content of a compound of the formula (I):
  • Figure US20100081695A1-20100401-C00017
      • based on the combined weight of the compound of the formula (I) and rosiglitazone maleate in the pharmaceutical composition, is 0.7% or less after storage of the sealed package at 75% relative humidity and 40° C. for 3 months.
  • In another embodiment of the sealed package, the pharmaceutical composition further comprises at least one disintegrant and at least one binder.
  • In another embodiment of the sealed package, the disintegrant is croscarmellose sodium, and the binder is povidone.
  • In another embodiment of the sealed package, the pharmaceutical composition further comprises a biguanide antidiabetic compound.
  • In another embodiment of the sealed package, the biguanide antidiabetic compound is a pharmaceutically acceptable salt of metformin.
  • In another embodiment of the sealed package, the pharmaceutically acceptable salt of metformin is metformin HCl.
  • In another embodiment of the sealed package, the pharmaceutical composition further comprises a sulfonyl urea antidiabetic compound.
  • In another embodiment of the sealed package, the sulfonyl urea antidiabetic compound is glimepride or glipizide.
  • In another embodiment of the sealed package, the pharmaceutical composition is in the form of a tablet.
  • In another embodiment of the sealed package, the tablet comprises a tablet core, the tablet core comprising, by weight, between 1% and 4% rosiglitazone maleate, 6% croscarmellose sodium, 2% povidone, between 0.5% and 1% magnesium stearate and between 87% and 90% filler, the filler consisting of lactose and microcrystalline cellulose.
  • In another embodiment of the sealed package, the tablet comprises a tablet core, the tablet core comprising, by weight, between 75% and 76% metformin HCl, between 0.2% and 1% rosiglitazone maleate, between 5% and 6% povidone, between 1% and 2% croscarmellose sodium, between 4% and 5% starch, and between 0.5% and 1% magnesium stearate.
  • In another embodiment of the sealed package, the desiccant is silica gel.
  • In another embodiment of the sealed package, the pharmaceutical composition is prepared by wet granulation with water.
  • In another embodiment of the sealed package, the sealed package is a HDPE bottle.
  • The subject invention also provides a process for making the pharmaceutical composition described herein, comprising
      • a) granulating in the presence of water a mixture of rosiglitazone maleate, croscarmellose sodium, povidone and a filler to obtain a granulate;
      • b) drying the granulate;
      • c) milling the granulate to obtain a milled granulate;
      • d) mixing the milled granulate with magnesium stearate to obtain a final blend; and
      • e) compressing the final blend into a tablet core.
  • In an embodiment of the process, steps c)-e) are performed in an atmosphere having a relative humidity of 30% or less.
  • The subject invention also provides another process for making the pharmaceutical composition described herein, comprising
      • a) granulating in the presence of an aqueous povidone solution a mixture comprising rosiglitazone maleate and metformin to obtain a granulate;
      • b) drying the granulate;
      • c) milling the granulate to obtain a milled granulate;
      • d) mixing the milled granulate with croscarmellose sodium and starch to obtain an first blend;
      • e) mixing the first blend with magnesium stearate to obtain a final blend; and
      • f) compressing the final blend into a tablet core.
  • In an embodiment of the process, steps c)-f) are performed in an atmosphere having a relative humidity of 30% or less.
  • In another embodiment, the process further comprises coating the tablet core with a film coating.
  • The subject invention also provides another process for preparing the pharmaceutical composition described herein or the sealed package described herein, comprising:
      • a. obtaining rosiglitazone maleate drug substance;
      • b. determining the total amount of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid present in the rosiglitazone maleate drug substance; and
      • c. including the rosiglitazone maleate drug substance in the preparation of the pharmaceutical composition only if the drug substance is determined to have less than 0.10% by weight of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid.
  • In an embodiment of the process, the pharmaceutical composition is prepared by wet granulation in an aqueous solution.
  • The subject invention also provides process for preparing a pharmaceutical composition comprising rosiglitazone maleate and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition comprises less than 1.2% of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid, based on the combined weight of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid and rosiglitazone maleate,
      • comprising:
        • a. obtaining rosiglitazone maleate drug substance;
        • b. determining the total amount of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid present in the rosiglitazone maleate drug substance; and
        • c. including the rosiglitazone maleate drug substance in the preparation of the pharmaceutical composition only if the drug substance is determined to have less than 0.10% by weight of 2-N-{5-[{4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid.
  • In an embodiment of the process, the pharmaceutical composition is prepared by wet granulation in an aqueous solution.
  • The subject invention also provides a process for validating a batch of a pharmaceutical composition containing rosiglitazone maleate and at least one pharmaceutically acceptable carrier for distribution comprising:
      • a. determining the total amount of 2-N-{5-[([4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid in a sample of the batch after stability testing; and
      • b. validating the batch for distribution only if the sample of the batch is determined in step a) to contain less than 1.2% by weight of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}butanedioic acid.
  • In an embodiment of the process, the batch is validated for distribution only if the sample of the batch is determined in step a) to contain less than 1.0% by weight of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid.
  • In another embodiment of the process, the batch is validated for distribution only if the sample of the batch is determined in step a) to contain less than 0.5% by weight of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid.
  • The subject invention also provides a process for making the isolated compound described herein, comprising:
      • a. contacting rosiglitazone maleate with water at a temperature of 40-100° C., and
      • b. isolating the compound from the reaction mixture of step a).
  • In an embodiment of the method, the compound is isolated from the mixture via chromatography.
  • In another embodiment of the method, the compound is isolated from the mixture via recrystallization.
  • The subject invention also provides a method for increasing insulin sensitivity in a human subject comprising administering to the human subject the pharmaceutical composition described herein.
  • The subject invention also provides use of the composition described herein or the pharmaceutical composition described herein for manufacturing a medicament for increasing insulin sensitivity in a human subject.
  • The subject invention also provides a the pharmaceutical composition described herein for increasing insulin sensitivity in a human subject.
  • One of the methods for determining the level of Compound 1 in rosiglitazone maleate drug substance:
  • (a) Measuring by HPLC the area under a peak corresponding to rosiglitazone in a reference standard at a known level;
    (b) Measuring by HPLC the area under a peak corresponding to Compound 1 in a sample comprising rosiglitazone maleate and Compound 1;
    (c) Determining the amount of Compound 1 in the sample by comparing the area of Step (a) to the area of Step (b) and taking into account the relative response factor between Compound 1 and rosiglitazone.
  • As used herein, “drug substance” or “DS” refers to the active ingredient in a drug product, which provides pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man or animals.
  • As used herein, “drug product” or “DP” refers to the finished dosage form containing the drug substance as well as at least one pharmaceutically acceptable carrier.
  • As used herein, a “sealed” package, container or coating substantially prevents the atmosphere from coming in contact with the contents of the package or container or with the material coated by the coating.
  • As used herein, a “HDPE” bottle refers to a bottle constructed of high density polyethylene plastic.
  • Impurities can be present in the active pharmaceutical ingredient (API) or in the pharmaceutical dosage form, for example, in tablets. In the case of impurities found in the pharmaceutical dosage form and not in the corresponding API, it is possible that the excipients in the dosage form cause the degradation of rosiglitazone maleate and thereby bring about the presence of impurities. It is possible that these impurities only come into being after time and are found as a result of long term or accelerated stability studies.
  • Generally, side products, by-products, and adjunct reagents (collectively “impurities”) are defined spectroscopically and or with another physical method, and then associated with a peak position, such as that in a chromatogram or a spot on a TLC plate. (Strobel, H. A.; Heineman, W. R., Chemical Instrumentation: A systematic Approach, 3rd ed. (Wiley & Sons: New York 1989) p. 953.) Thereafter, the impurity can be identified by its position in the chromatogram where the position in a chromatogram is conventionally measured in minutes between injection of the sample on the column and elution of the particular component through the detector.
  • The retention time can vary based upon the condition of the instrumentation, as well as many other factors. To mitigate the effects such variations have upon accurate identification of an impurity, practitioners use the “Relative retention time,” (RRT) to identify impurities. (Strobel p. 922) The RRT of an impurity is defined as the retention time of the impurity divided by the retention time of a reference marker. It may be advantageous to select a compound other than the API that is added to the mixture in an amount sufficiently large to be detectable and sufficiently low as not to saturate the column and to use that compound as the reference marker for determination of the RRT.
  • A reference standard is a compound in a relatively pure state, used to quantify the amount of the compound in an unknown mixture. A reference standard can be used as either an external standard or as an internal standard.
  • An external standard is employed when a solution of a known concentration of the reference standard and an unknown mixture are analyzed using the same technique. The amount of the compound in the mixture can be determined by comparing the magnitude of the detector responses.
  • An internal standard is employed when an unknown mixture contains a detectable amount of the reference standard compound without addition of the reference standard. The amount of internal standard is determined by preparing at least two samples by adding known and differing amounts of the internal standard. The proportion of the detector response due to the reference standard present in the mixture can be determined by plotting the detector response attained for each of the samples against the amount of the reference standard added to each of the samples and extrapolating the plot to zero.
  • The compositions may be prepared as medicaments to be administered orally, parenterally, rectally or transdermally. Suitable forms for oral administration include tablets, compressed or coated pills, dragees, sachets, hard or soft gelatin capsules, sublingual tablets, syrups and suspensions; for parenteral administration the invention provides ampoules or vials that include an aqueous or non-aqueous solution or emulsion; for rectal administration there are provided suppositories with hydrophilic or hydrophobic vehicles; and for topical application as ointments and transdermal delivery there are provided suitable delivery systems as known in the art.
  • Specific examples of pharmaceutical acceptable carriers and excipients that may be used to formulate oral dosage forms of the present invention are described, e.g., in U.S. Pat. No. 6,126,968 to Peskin et al., issued Oct. 3, 2000. Techniques and compositions for making dosage forms useful in the present invention are described-in the following references: 7 Modern Pharmaceutics, Chapters 9 and 10 (Banker & Rhodes, Editors, 1979); Pharmaceutical Dosage Forms: Tablets (Lieberman et al., 1981); Ansel, Introduction to Pharmaceutical Dosage Forms 2nd Edition (1976); Remington's Pharmaceutical Sciences, 17th ed. (Mack Publishing Company, Easton, Pa., 1985); Advances in Pharmaceutical Sciences (David Ganderton, Trevor Jones, Eds., 1992); Advances in Pharmaceutical Sciences Vol 7. (David Ganderton, Trevor Jones, James McGinity, Eds., 1995); Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms (Drugs and the Pharmaceutical Sciences, Series 36 (James McGinity, Ed., 1989); Pharmaceutical Particulate Carriers: Therapeutic Applications: Drugs and the Pharmaceutical Sciences, Vol 61 (Alain Rolland, Ed., 1993); Drug Delivery to the Gastrointestinal Tract (Ellis Horwood Books in the Biological Sciences. Series in Pharmaceutical Technology; J. G. Hardy, S. S. Davis, Clive G. Wilson, Eds.); Modern Pharmaceutics Drugs and the Pharmaceutical Sciences, Vol 40 (Gilbert S. Banker, Christopher T. Rhodes, Eds.).
  • Tablets may contain suitable binders, lubricants, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents. For instance, for oral administration in the dosage unit form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, gelatin, agar, starch, sucrose, glucose, methyl cellulose, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, microcrystalline cellulose and the like. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn starch, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, povidone, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, sodium benzoate, sodium acetate, sodium chloride, stearic acid, sodium stearyl fumarate, talc and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, croscarmellose sodium, sodium starch glycolate and the like.
    • EXPERIMENTAL DETAILS Example 1 Isolation of Compound 1 by Preparative HPLC
  • 1 g of rosiglitazone maleate was mixed with 1 g of water in a reaction vessel with screw cap. The mixture was kept at 70° C. for 5 days. To this mixture, 24 mL of methanol: water solution of trifluoroacetic acid (with a pH of about 2.8) (3:2) were added. The rosiglitazone base concentration of the solution was 40 mg/mL.
  • Preparative HPLC was performed to the solution using the following conditions:
    • Column & Packing: Semi-preparative, Luna 5μ C18(2). 250×10 mm.
    • Column Temperature: Ambient
    • Mobile Phase: Solution A—100% Water. Solution B—50:50 Water:Acetonitrile.
  • Elution proceeded according to the following schedule:
  • Time (min) % Solution A % Solution B
    0 75 25
    20 50 50
    45 0 100
    48 0 100
    50 75 25
    52 75 25

    Flow Rate: 7.0 mL/min
    Detector: UV at 245 nm, 10 mm flow cell path length
    • Injection Volume: 200 μL Injector Wash Solution: Solution B.
  • The peaks of interest eluted at approximately 33 minutes. Separated fractions of Compound 1 were analyzed by HPLC. The relevant fractions were concentrated in vacuo using rotor evaporator and lyophilized. The obtained yield was about 8 mg. The obtained compound was determined to be Compound 1.
  • Figure US20100081695A1-20100401-C00018
  • The compound was analyzed using NMR and the following spectra were attained:
  • Atom # 1H 13C
     1 — 157.89
     2 6.66 105.89
     3 7.51 137.45
     4 6.57 111.52
     5 8.08 147.26
     6 3.07 37.03
     7 3.90 48.52
     8 4.11 65.33
     9 — 157.56
    10 6.87 114.39
    11 7.15 130.29
    12 — 128.27
    13 3.39, 3.00 36.55
    14 4.99 50.66
    15 — 173.22
    16 — 170.37
    NH — —
     1′ — 171.20
     2′ 5.09 50.66
     3′ 3.05, 2.65 33.02
     4′ — 168.98
  • MH+MS=473 mass units. This data and the NMR analysis confirmed that Compound 1 was attained.
    • Example 2 Isolation of Compound 1 by Crystallization
  • 1.3 g of rosiglitazone maleate was mixed with 1.3 g of water in a reaction vessel with screw cap. The mixture was kept at 70° C. for 5 days. 4 ml of methanol: water solution of trifluoroacetic acid with a pH of about 2.8 (3:2) were added to the mixture.
  • The sample was stored at 2-8° C. for 5 days. Crystals of rosiglitazone maleate enriched with Compound 1 precipitated spontaneously from the sample. These crystals were vacuum-filtered and washed with cold water and methanol. These crude crystals were then dissolved in hot isopropyl alcohol and cooled in an ice bath until crystals of Compound 1 appeared. The crystals were vacuum-filtered then washed with cold isopropyl alcohol, methanol and dried to yield 40 mg. Purity: about 97-98%.
    • Example 3 HPLC Analysis of Compound 1 Present in Rosiglitazone Maleate DS Column & Packing: Zorbax Eclipse XDB C8, 5μ, 150×4.6 mm Column Temperature: 30° C.
  • Mobile Phase Buffer at pH 2.8 (20 mM sodium dihydrogen phosphate and 10 mM sodium pentanesulfonate solution): acetonitrile (80/20)
    Flow Rate: 1.5 mL/min
    Detector: UV at 245 nm, 10 mm flow cell path length
    • Injection Volume: 20 μL Standard Solution Preparation:
  • Rosiglitazone maleate analytical standard was dissolved in diluent to make a solution with a concentration of approximately 0.2 μg/mL in terms of rosiglitazone.
    • Sample Preparation:
  • 20 mg of the rosiglitazone maleate raw material was weighed into a 25 ml volumetric flask and dissolved in diluent.
  • The standard and samples were injected and the peak due to Compound 1 was monitored and calculated in the relevant sample. The peak which corresponded to Compound 1 was found to elute at approximately a Relative Retention Time of 0.7, when compared to the rosiglitazone maleate peak.
    • Example 4 HPLC Method for Determining Presence of Compound 1 in Formulation of Rosiglitazone Maleate Tablets or in Combined Formulation of Rosiglitazone Maleate and Metformin HCl Tablets Column & Packing: Zorbax Eclipse XDB C8, 5μ, 150×4.6 mm Column Temperature: 30° C.
  • Mobile Phase: Solution A—20 mM sodium dihydrogen phosphate and
    10 mM sodium pentanesulfonate solution at pH 2.8.
    Solution B—75% Solution A and 25% acetonitrile.
  • Elution proceeded according to the following schedule:
  • Time (min) Solution A % Solution B %
    0 50 50
    15 0 100
    22 0 100
    24 50 50
    28 50 50

    Flow Rate: 1.5 mL/min
    Detector: UV at 245 nm, 10 mm flow cell path length
    • Injection Volume: 15 μL Standard Solution
  • Rosiglitazone maleate analytical standard was diluted with diluent to a concentration of 0.1 μg/mL.
    • Sample Solution Preparation
  • Tablets were dissolved and diluted based on the declared strengths.
  • The standard and samples were injected and the peaks due to Compound 1 were monitored and calculated in the relevant sample.
  • The quantifiable limit of this method was determined to be 0.1% based on the combined weight of Compound 1 and rosiglitazone.
    • Example 5a Preparation of Tablets Comprising Rosiglitazone Maleate and Metformin
  • Tablets were prepared using the excipients in Table 1.
  • TABLE 1
    Metformin HCl/ Metformin HCl/ Metformin HCl/
    Rosiglitazone Rosiglitazone Rosiglitazone
    Maleate Maleate Maleate
    500/1 & 1000/2 mg 500/2 & 1000/4 mg 500/4 mg
    MATERIAL % W/W % W/W % W/W
    Part I
    Metformin HCl 75.76 75.6 75.0
    Povidone USP (PVP 3.03 3.03 3.01
    K-30)
    Part II
    Microcrystalline 2.88 2.87 2.86
    Cellulose NF
    Colloidal 0.03 0.03 0.03
    Silicon Dioxide
    Part III
    Rosiglitazone 0.20 0.4 0.80
    Maleate
    Microcrystalline 2.88 2.87 2.86
    Cellulose NF
    Part IV
    Microcrystalline 0.30 0.30 0.30
    Cellulose NF
    Granulation
    Solution:
    Povidone USP 2.73 2.72 2.71
    (PVP K-90) in
    hot purified
    water
    Part V
    Croscarmellose 1.59 1.59 1.58
    Sodium NF-
    Microcrystalline 5.30 5.3 5.27
    Cellulose NF-
    Starch NF 4.39 4.34 4.37
    Part VI
    Magnesium 0.91 0.91 0.90
    Stearate NF
    Total (Cores) 100.0 100.0 100.0
    Film coating (% 3.0 3.0 3.0
    calculated as
    per core weight)

    1. Metformin HCl & Povidone (PVP K-30) of Part I were transferred to a high shear mixer and mixed.
    2. Microcrystalline cellulose and Colloidal Silicon Dioxide of part II were screened and mixed in a Y-cone mixer with Rosiglitazone and Microcrystalline cellulose of Part III and with Microcrystalline cellulose of part IV.
    3. The mixture from Step 2 was transferred to the high shear mixer from Step 1 and mixed.
    4. Povidone (PVP K-90) solution in hot purified water was added to the high shear mixer from Step 3 & was mixed to attain a wet granulate.
    5. The granulate from Step 4 was dried in a Fluid Bed Dryer.
  • Steps 6 to 10 which follow were performed in an atmosphere with lower than 30% relative humidity.
  • 6. The dried granulate was milled and transferred to a Flow bin or Y-cone.
    7. Components of part V were screened through a sieve, transferred to Flow bin or Y-Cone from Step 6, and mixed.
    8. Magnesium stearate was screened through a sieve, transferred to Flow bin or Y-cone from Step 7, and mixed to get the final blend.
    9. The final blend from Step 8 was compressed into cores in a tableting machine to yield tablet cores of the appropriate dosages.
    10. The cores were coated using OPADRY®, which consists of HPMC2910/HYPROMELLOSE 6 cP, Titanium dioxide, Macrogol/PEG 400, Iron Oxide yellow/iron oxide red; using a coating machine.
    • Example 5b Preparation of Tablets Comprising Rosiglitazone Maleate
  • Tablets were prepared using the excipients below.
  • Rosiglitazone Rosiglitazone Rosiglitazone
    Maleate Tabs Maleate Tabs Maleate Tabs
    (2 mg base) (4 mg base) (8 mg base)
    MATERIAL % W/W % W/W % W/W
    Part I
    Lactose Monohydrate 45.2 44.33 44.33
    NF
    Croscarmellose 6.0 6.0 6.0
    Sodium NF
    Rosiglitazone Maleate 1.77 3.53 3.53
    Povidone USP 2.0 2.0 2.0
    (PVP K-30)
    Microcrystalline 44.36 43.47 43.47
    Cellulose NF
    Purified water USP as needed as needed as needed
    Part II
    Magnesium Stearate 0.67 0.67 0.67
    NF
    Total (Cores) 100.0 100.0 100.0
    Film coating(% 3.0 3.0 3.0
    calculated as per core
    weight)
    • Production Method
  • 1. The components of Part I were transferred to a high shear mixer and mixed.
    2. Purified water (granulation solution) was added to the high shear mixer from Step 1 and mixed, and a wet granulate was attained.
    3. The granulate from Step 2 was dried in a Fluid Bed Dryer.
  • Steps 4 to 7 which follow were performed in an atmosphere with lower than 30% relative humidity.
  • 4. The dried granulate was milled and transferred to a flow bin or Y-cone and mixed.
    5. Magnesium stearate was screened through a sieve, transferred to the flow bin or Y-cone from Step 4 and mixed to attain the final blend.
    6. The final blend from Step 5 was compressed in to cores in a tableting machine.
    7. The cores were coated in a coating machine using Opadry® which consists of: HPMC2910/HYPROMELLOSE 6 cP, Titanium dioxide, Macrogol/PEG 3350, Triacetin/Glycerol, Triacetate, Talc, Iron Oxide yellow/red/black, FD&C Blue#2/Indigo Carmine Aluminum Lake.
    • Example 6 Thermodegradation Study
  • Two batches of Rosiglitazone maleate drug substance were analyzed for presence of Compound 1 after thermodegradation, and after storage at RT, using the method described in Example 4.
  • Also, drug product (500 mg metformin/4 mg rosiglitazone base) prepared as in Example 5a made from two different batches of the rosiglitazone maleate drug substance was analyzed for presence of Compound 1 before and after thermodegradation using the method described in Example 4.
  • The thermodegradation was performed by subjecting the samples to 65° C. heat and 100% relative humidity for 5 days. The content of Compound 1 is listed in the table below. The peaks were measured and the area percent (area of Compound 1 peak/area of all rosiglitazone related peaks) of the Compound 1 peak is listed below.
  • Content of Compound Content of Compound
    1 without thermo- 1 after thermo-
    Sample degradation % (w/w) degradation % (w/w)
    DS A 0.0 0.03
    DS B 0.16 0.18
    DP A 0.0 0.68
    DP B 0.15 1.05
  • This Example shows that Compound 1 is formed to a greater extent in DP than in the DS.
    • Example 7 Compatibility Study
  • Rosiglitazone maleate was mixed with various excipients and with metformin in the same proportions as present in the 500 mg/4 mg (base strength) metformin/rosiglitazone maleate tablets. 0.5 ml of water was added to each mixture, and the samples were kept at 65° C. for 4 days. The amount of Compound 1 was determined in each of the samples using the method in Example 4. The results are summarized in the table below. The peaks were measured and the area percent (area of Compound 1 peak/area of all rosiglitazone related peaks) of the Compound 1 peak is listed below.
  • Sample Area Percent
    Rosiglitazone Maleate (alone) 0.9
    PVP K90 1.3
    PVP K30 1.5
    Metformin HCl 0.2
    Avicel 2.9
    Croscarmellose 0.3
    Starch 6.7
    Mg Stearate 0.3
    Placebo mix A 0.1
    Placebo mix B 0.1
  • Placebo mix A refers to a mixture of excipients as indicated in Example 5a, with the exception of rosiglitazone maleate.
  • Placebo mix B refers to a mixture of excipients as indicated in Example 5b, with the exception of rosiglitazone maleate.
  • This Example indicates that the presence of moisture and some excipients, especially starch, enhances the production of Compound 1 in accelerated conditions.
    • Example 8 Stability of Tablets
  • Tablets were prepared as described in Example 5. 100 tablets were packed into high density polyethylene (HDPE) bottles either with or without silica gel and were stored at 75% RH and 40° C. for 3 months. The tablets were then tested for Compound 1. The results, in terms of percentage of Compound 1 are listed in the table below. The percentage of compound in all of the dosages in the table below before the stability testing was less than 0.1%.
  • Stored without Stored with
    Tablets silica gel silica gel
    500/1 mg 0.7 0.4
    1000/2 mg  0.6 0.4
    500/2 mg 0.8 0.5
    1000/4 mg  1.0 0.5
    500/4 mg 1.3 0.7
  • It can be seen from this experiment that the absence of water in pharmaceutical compositions comprising rosiglitazone maleate enhances stability. Addition of silica gel to packaging of pharmaceutical compositions comprising rosiglitazone maleate reduces the formation of Compound 1.
    • Example 9 Measurement of Content of Compound 1 in AVANDAMET® 1000/2 mg tablets
  • The amount of Compound 1 in commercially available AVANDAMET® tablets 1000/2 mg was analyzed using Example 4. Compound 1 was present in an amount that was less than quantifiable.

Claims (24)

1-51. (canceled)
52. A process for making a pharmaceutical composition comprising a compound having the formula (I):
Figure US20100081695A1-20100401-C00019
in an amount of at least 0.2% based on the weight of the composition, and a carrier, or
a pharmaceutical composition comprising a granulate of a mixture of:
a) rosiglitazone maleate;
b) at least one pharmaceutically acceptable carrier; and
c) the compound of the formula (I) present in an amount of less than 0.1%, based on the combined weight of the compound of the formula (I) and rosiglitazone maleate,
wherein the pharmaceutical composition is in the form of a tablet comprising a tablet core, the tablet core comprising, by weight, between 1% and 4% rosiglitazone maleate, 6% croscarmellose sodium, 2% povidone, between 0.5% and 1% magnesium stearate and between 87% and 90% filler, the filler consisting of lactose and microcrystalline cellulose,
the process comprising
a) granulating in the presence of water a mixture of rosiglitazone maleate, croscarmellose sodium, povidone and a filler to obtain a granulate;
b) drying the granulate;
c) milling the granulate to obtain a milled granulate;
d) mixing the milled granulate with magnesium stearate to obtain a final blend; and
e) compressing the final blend into a tablet core.
53. The process of claim 52, wherein steps c)-e) are performed in an atmosphere having a relative humidity of 30% or less.
54. A process for making a pharmaceutical composition comprising a compound having the formula (I):
Figure US20100081695A1-20100401-C00020
in an amount of at least 0.2% based on the weight of the composition, and a carrier,
or
a pharmaceutical composition comprising a granulate of a mixture of:
a) rosiglitazone maleate;
b) at least one pharmaceutically acceptable carrier; and
c) the compound of the formula (I) present in an amount of less than 0.1%, based on the combined weight of the compound of the formula (I) and rosiglitazone maleate,
wherein the pharmaceutical composition is in the form of a tablet comprising a tablet core, the tablet core comprising, by weight, between 75% and 76% metformin HCl, between 0.2% and 1% rosiglitazone maleate, between 5% and 6% povidone, between 1% and 2% croscarmellose sodium, between 4% and 5% starch, and between 0.5% and 1% magnesium stearate,
the process comprising
a) granulating in the presence of an aqueous povidone solution a mixture comprising rosiglitazone maleate and metformin to obtain a granulate;
b) drying the granulate;
c) milling the granulate to obtain a milled granulate;
d) mixing the milled granulate with croscarmellose sodium and starch to obtain an first blend;
mixing the first blend with magnesium stearate to obtain a final blend; and
f) compressing the final blend into a tablet core.
55. The process of claim 54, wherein steps c)-f) are performed in an atmosphere having a relative humidity of 30% or less.
56. The process of any of claims 52-55, further comprising coating the tablet core with a film coating.
57. A process for preparing pharmaceutical composition comprising
a granulate of a mixture of:
a) rosiglitazone maleate;
b) at least one pharmaceutically acceptable carrier; and
c) a compound of the formula (I):
Figure US20100081695A1-20100401-C00021
which is present in an amount of less than 0.1%, based on the combined weight of the compound of the formula (I) and rosiglitazone maleate, or
a sealed package comprising a pharmaceutical composition comprising a compound having the formula (I) which is present in an amount of at least 0.2% based on the weight of the composition, and a carrier,
the process comprising:
a) obtaining rosiglitazone maleate drug substance;
b) determining the total amount of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid present in the rosiglitazone maleate drug substance; and
c) including the rosiglitazone maleate drug substance in the preparation of the pharmaceutical composition only if the drug substance is determined to have less than 0.10% by weight of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid.
58. The process of claim 57, wherein the pharmaceutical composition is prepared by wet granulation in an aqueous solution.
59. (canceled)
60. (canceled)
61. A process for producing a validated batch of a pharmaceutical composition containing rosiglitazone maleate and at least one pharmaceutically acceptable carrier for distribution comprising:
a) producing a batch of the pharmaceutical product;
b) determining the total amount of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid in a sample of the batch after stability testing; and
c) validating the batch for distribution only if the sample of the batch is determined in step a) to contain less than 1.2% by weight of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid.
62. The process of claim 61, wherein the batch is validated for distribution only if the sample of the batch is determined in step b) to contain less than 1.0% by weight of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid.
63. The process of claim 62, wherein the batch is validated for distribution only if the sample of the batch is determined in step b) to contain less than 0.5% by weight of 2-N-{5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione}-butanedioic acid.
64. A process for making an isolated compound of the formula:
Figure US20100081695A1-20100401-C00022
comprising:
a) contacting rosiglitazone maleate with water at a temperature of 40-100° C., and
b) isolating the compound from the reaction mixture of step a).
65. The process of claim 64, wherein the compound is isolated from the mixture via chromatography.
66. The process of claim 64, wherein the compound is isolated from the mixture via recrystallization.
67-69. (canceled)
70. The process of claim 52, wherein the pharmaceutical composition comprising a compound having the formula (I) present in an amount of at least 1.5% based on the weight of the composition, and a carrier.
71. The process of claim 52, wherein the pharmaceutical composition comprising a compound having the formula (I) present in an amount of at least 50% based on the weight of the composition, and a carrier.
72. The process of claim 54, wherein the pharmaceutical composition comprising a compound having the formula (I) present in an amount of at least 1.5% based on the weight of the composition, and a carrier.
73. The process of claim 54, wherein the pharmaceutical composition comprising a compound having the formula (I) present in an amount of at least 50% based on the weight of the composition, and a carrier.
74. The process of claim 57, wherein the sealed package further comprising a desiccant.
75. The process of claim 74, wherein the desiccant is silica gel.
76. The process of claim 57, wherein the sealed package is a HDPE bottle.
US12/592,442 2006-05-09 2009-11-24 2-N-{5-[ [4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate Abandoned US20100081695A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/592,442 US20100081695A1 (en) 2006-05-09 2009-11-24 2-N-{5-[ [4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/430,582 US7435741B2 (en) 2006-05-09 2006-05-09 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US11/584,311 US7632841B2 (en) 2006-05-09 2006-10-20 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US12/592,442 US20100081695A1 (en) 2006-05-09 2009-11-24 2-N-{5-[ [4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/584,311 Division US7632841B2 (en) 2006-05-09 2006-10-20 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate

Publications (1)

Publication Number Publication Date
US20100081695A1 true US20100081695A1 (en) 2010-04-01

Family

ID=38685933

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/430,582 Expired - Fee Related US7435741B2 (en) 2006-05-09 2006-05-09 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US11/584,311 Expired - Fee Related US7632841B2 (en) 2006-05-09 2006-10-20 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US12/592,442 Abandoned US20100081695A1 (en) 2006-05-09 2009-11-24 2-N-{5-[ [4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US11/430,582 Expired - Fee Related US7435741B2 (en) 2006-05-09 2006-05-09 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US11/584,311 Expired - Fee Related US7632841B2 (en) 2006-05-09 2006-10-20 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate

Country Status (1)

Country Link
US (3) US7435741B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106706769A (en) * 2015-11-17 2017-05-24 重庆医药工业研究院有限责任公司 Separation and determination method of empagliflozin and optical isomers thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20070293546A1 (en) * 2006-06-15 2007-12-20 Srinivasula Reddy Maddula Preparation of rosiglitazone and its salts
WO2010013141A2 (en) * 2008-08-01 2010-02-04 Actavis Group Ptc Ehf Substantially pure rosiglitazone hydrogen sulfate
CN106349245B (en) * 2016-08-09 2018-12-04 重庆植恩药业有限公司 A kind of phosphoric acid Xi Gelieting impurity and its preparation method and application

Citations (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
US5002953A (en) * 1987-09-04 1991-03-26 Beecham Group P.L.C. Novel compounds
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5910592A (en) * 1992-09-05 1999-06-08 Smithkline Beecham Plc Substituted thiazolidinedione derivatives
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5952356A (en) * 1995-06-20 1999-09-14 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US20020099081A1 (en) * 1997-12-16 2002-07-25 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020115866A1 (en) * 2000-12-26 2002-08-22 Torrent Pharmaceuticals Ltd. Process for the preparation of pyridine derivative
US20020133016A1 (en) * 1997-12-16 2002-09-19 Smithkline Beecham P.L.C. Substituted thiazolidined derivative, process for its preparation and its pharmaceutical use
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US20020156106A1 (en) * 1994-02-10 2002-10-24 Smithkline Beecham P.L.C. Use of insulin sensitisers for treating renal diseases
US20030092742A1 (en) * 1997-11-04 2003-05-15 Smithkline Beecham P.L.C. Process for the preparation of thiazolidinedione derivatives
US20030125358A1 (en) * 1999-08-17 2003-07-03 Smithkline Beecham P.L.C. Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation
US20030149054A1 (en) * 1988-08-30 2003-08-07 Beecham Group P.L.C. Novel compounds
US20030162815A1 (en) * 2000-06-08 2003-08-28 Craig Andrew Simon Thiazolidinedione salt for treatment of diabetes mellitus
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
US20030220373A1 (en) * 2000-03-09 2003-11-27 Michael Jaye Therapeutic uses of PPAR mediators
US20040014791A1 (en) * 2000-09-07 2004-01-22 Craig Andrew Simon Thiazolidinedione derivative and its use as antidiabetic
US20040014790A1 (en) * 2000-08-04 2004-01-22 Craig Andrew Simon Tartrate salt of thiazolidinedione derivative
US20040024027A1 (en) * 2000-06-08 2004-02-05 Craig Andrew Simon 5(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical
US20040029926A1 (en) * 2000-09-05 2004-02-12 Craig Andrew Simon Thiazolidinone nitrate salt
US20040034066A1 (en) * 2000-09-06 2004-02-19 Craig Andrew Simon Hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]thiazolidine-2,4-dione
US20040044043A1 (en) * 2000-09-05 2004-03-04 Craig Andrew Simon Thiazolidinedione derivative and its use as antidiabetic
US20040048899A1 (en) * 2000-08-04 2004-03-11 Choudary Bernadette Marie Tartrate salts of thiazollidnedione derivative
US20040068116A1 (en) * 2000-09-26 2004-04-08 Prabhakar Chebiyyam Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
US20040082620A1 (en) * 2000-12-22 2004-04-29 Craig Andrew Simon 5'-4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione mesylate salt
US20040087629A1 (en) * 2000-08-04 2004-05-06 Choudary Berndette Marie Tartrate salts of thiazolidinedione derivative
US20040092555A1 (en) * 1999-04-23 2004-05-13 Smithkline Beecham Pic Pharmaceutical compositions of a thiazolidinedione derivative and their use as antidiabetics
US20040097556A1 (en) * 1997-06-18 2004-05-20 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and sulphonylurea
US20040102485A1 (en) * 2000-08-04 2004-05-27 Craig Andrew Simon Tartrate salt of thiazolidinedione derivative
US20040106649A1 (en) * 1999-04-14 2004-06-03 Hiroyuki Odaka Agent for improving acidosis
US20040122031A1 (en) * 2002-03-22 2004-06-24 Hong Chung-Ll Thiazolidinedione and pharmaceutical composition comprising the same
US20040214866A1 (en) * 2000-09-29 2004-10-28 Smithkline Beecham P.L.C. Sodium salts of 5-'4-'2-(N-methyl-N-(2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione
US20040219212A1 (en) * 2001-05-23 2004-11-04 Catherine Castan Single-daily dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active principle
US20040248945A1 (en) * 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
US20040266833A1 (en) * 2000-11-14 2004-12-30 Buckingham Robin Edwin Novel use of certain insulin sensitizers or ppar-gamma agonists
US20050014798A1 (en) * 2003-04-18 2005-01-20 Chemi Spa Polymorphous forms of rosiglitazone maleate
US20050043539A1 (en) * 2004-01-28 2005-02-24 Gediya Lalji Karsan Process for the preparation of 5-[4-[2-[N-methyl-N-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate
US20050112198A1 (en) * 2003-10-27 2005-05-26 Challapalli Prasad V. Bupropion formulation for sustained delivery
US20050163837A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone formulations
US20070265312A1 (en) * 2006-05-09 2007-11-15 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20070296546A1 (en) * 1998-02-17 2007-12-27 Sia Yik H Code based access systems

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0579733B1 (en) 1991-04-11 2001-06-20 PHARMACIA & UPJOHN COMPANY Thiazolidinedione derivatives, production and use thereof
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
GB9711683D0 (en) 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
ID23372A (en) 1997-06-18 2000-04-20 Smithkline Beecham Plc TREATMENT OF DIABETES WITH TIAZOLIDINDION AND METFORMIN
WO1999059586A1 (en) 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
ITMI20011295A1 (en) 2001-06-20 2002-12-20 Giuseppe Catalfamo ABRASIVE BODY INTENDED FOR SURFACE PROCESSING AND SUPPORT FOR SURFACE PROCESSING EQUIPPED WITH SUCH BODY
US20070293546A1 (en) * 2006-06-15 2007-12-20 Srinivasula Reddy Maddula Preparation of rosiglitazone and its salts

Patent Citations (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214848B1 (en) * 1985-06-20 2001-04-10 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
US5002953A (en) * 1987-09-04 1991-03-26 Beecham Group P.L.C. Novel compounds
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US20030149054A1 (en) * 1988-08-30 2003-08-07 Beecham Group P.L.C. Novel compounds
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5910592A (en) * 1992-09-05 1999-06-08 Smithkline Beecham Plc Substituted thiazolidinedione derivatives
US20030109552A1 (en) * 1994-02-10 2003-06-12 Smithkline Beecham P.L.C. Use of insulin sensitisers for treating renal diseases
US20020156106A1 (en) * 1994-02-10 2002-10-24 Smithkline Beecham P.L.C. Use of insulin sensitisers for treating renal diseases
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6156773A (en) * 1995-06-20 2000-12-05 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6172089B1 (en) * 1995-06-20 2001-01-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6133293A (en) * 1995-06-20 2000-10-17 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6133295A (en) * 1995-06-20 2000-10-17 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6150383A (en) * 1995-06-20 2000-11-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6150384A (en) * 1995-06-20 2000-11-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6121295A (en) * 1995-06-20 2000-09-19 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6166042A (en) * 1995-06-20 2000-12-26 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6166043A (en) * 1995-06-20 2000-12-26 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6169099B1 (en) * 1995-06-20 2001-01-02 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6169100B1 (en) * 1995-06-20 2001-01-02 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6121294A (en) * 1995-06-20 2000-09-19 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6174904B1 (en) * 1995-06-20 2001-01-16 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6211207B1 (en) * 1995-06-20 2001-04-03 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6211206B1 (en) * 1995-06-20 2001-04-03 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6211205B1 (en) * 1995-06-20 2001-04-03 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6103742A (en) * 1995-06-20 2000-08-15 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6080765A (en) * 1995-06-20 2000-06-27 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US5952356A (en) * 1995-06-20 1999-09-14 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US20030216443A1 (en) * 1995-06-20 2003-11-20 Hitoshi Ikeda Pharmaceutical composition
US5965584A (en) * 1995-06-20 1999-10-12 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US20040097556A1 (en) * 1997-06-18 2004-05-20 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and sulphonylurea
US20030092742A1 (en) * 1997-11-04 2003-05-15 Smithkline Beecham P.L.C. Process for the preparation of thiazolidinedione derivatives
US20030139604A1 (en) * 1997-12-16 2003-07-24 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
US20050288513A1 (en) * 1997-12-16 2005-12-29 Smithkline Beecham Plc Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
US20020099081A1 (en) * 1997-12-16 2002-07-25 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US20020133016A1 (en) * 1997-12-16 2002-09-19 Smithkline Beecham P.L.C. Substituted thiazolidined derivative, process for its preparation and its pharmaceutical use
US20030120078A1 (en) * 1997-12-16 2003-06-26 Smithkline Beecham Plc 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, hydrate as pharmaceutical
US20040214865A1 (en) * 1997-12-16 2004-10-28 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US20070296546A1 (en) * 1998-02-17 2007-12-27 Sia Yik H Code based access systems
US20040106649A1 (en) * 1999-04-14 2004-06-03 Hiroyuki Odaka Agent for improving acidosis
US20040092555A1 (en) * 1999-04-23 2004-05-13 Smithkline Beecham Pic Pharmaceutical compositions of a thiazolidinedione derivative and their use as antidiabetics
US20040248945A1 (en) * 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
US20030125358A1 (en) * 1999-08-17 2003-07-03 Smithkline Beecham P.L.C. Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation
US20030220373A1 (en) * 2000-03-09 2003-11-27 Michael Jaye Therapeutic uses of PPAR mediators
US20040024027A1 (en) * 2000-06-08 2004-02-05 Craig Andrew Simon 5(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical
US20030162815A1 (en) * 2000-06-08 2003-08-28 Craig Andrew Simon Thiazolidinedione salt for treatment of diabetes mellitus
US20040102485A1 (en) * 2000-08-04 2004-05-27 Craig Andrew Simon Tartrate salt of thiazolidinedione derivative
US20040014790A1 (en) * 2000-08-04 2004-01-22 Craig Andrew Simon Tartrate salt of thiazolidinedione derivative
US20040087629A1 (en) * 2000-08-04 2004-05-06 Choudary Berndette Marie Tartrate salts of thiazolidinedione derivative
US20040048899A1 (en) * 2000-08-04 2004-03-11 Choudary Bernadette Marie Tartrate salts of thiazollidnedione derivative
US20040029926A1 (en) * 2000-09-05 2004-02-12 Craig Andrew Simon Thiazolidinone nitrate salt
US20040044043A1 (en) * 2000-09-05 2004-03-04 Craig Andrew Simon Thiazolidinedione derivative and its use as antidiabetic
US20050282867A1 (en) * 2000-09-06 2005-12-22 Smithkline Beecham P.L.C. Hydrochloride salt of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazo-lidine-2,4-dione
US20040034066A1 (en) * 2000-09-06 2004-02-19 Craig Andrew Simon Hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]thiazolidine-2,4-dione
US20040014791A1 (en) * 2000-09-07 2004-01-22 Craig Andrew Simon Thiazolidinedione derivative and its use as antidiabetic
US20040068116A1 (en) * 2000-09-26 2004-04-08 Prabhakar Chebiyyam Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
US20050277679A9 (en) * 2000-09-29 2005-12-15 Smithkline Beecham P.L.C. Sodium salts of 5-'4-'2-(N-methyl-N-(2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione
US20060004058A1 (en) * 2000-09-29 2006-01-05 Smithkline Beecham Plc Sodium salts of 5-'4-'2-(N-methyl-N-(2-pyridyl) amino) ethoxy!benzyl!thiazolidine -2, 4-dione
US20040214866A1 (en) * 2000-09-29 2004-10-28 Smithkline Beecham P.L.C. Sodium salts of 5-'4-'2-(N-methyl-N-(2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione
US20040266833A1 (en) * 2000-11-14 2004-12-30 Buckingham Robin Edwin Novel use of certain insulin sensitizers or ppar-gamma agonists
US20060040993A1 (en) * 2000-12-22 2006-02-23 Smithkline Beecham Plc 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione Mesylate salt
US20040082620A1 (en) * 2000-12-22 2004-04-29 Craig Andrew Simon 5'-4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione mesylate salt
US20020115866A1 (en) * 2000-12-26 2002-08-22 Torrent Pharmaceuticals Ltd. Process for the preparation of pyridine derivative
US20040219212A1 (en) * 2001-05-23 2004-11-04 Catherine Castan Single-daily dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active principle
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
US20040122031A1 (en) * 2002-03-22 2004-06-24 Hong Chung-Ll Thiazolidinedione and pharmaceutical composition comprising the same
US20050014798A1 (en) * 2003-04-18 2005-01-20 Chemi Spa Polymorphous forms of rosiglitazone maleate
US20050112198A1 (en) * 2003-10-27 2005-05-26 Challapalli Prasad V. Bupropion formulation for sustained delivery
US20050163837A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone formulations
US20050043539A1 (en) * 2004-01-28 2005-02-24 Gediya Lalji Karsan Process for the preparation of 5-[4-[2-[N-methyl-N-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate
US20070265312A1 (en) * 2006-05-09 2007-11-15 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US7632841B2 (en) * 2006-05-09 2009-12-15 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106706769A (en) * 2015-11-17 2017-05-24 重庆医药工业研究院有限责任公司 Separation and determination method of empagliflozin and optical isomers thereof

Also Published As

Publication number Publication date
US20070265312A1 (en) 2007-11-15
US7435741B2 (en) 2008-10-14
US20070265313A1 (en) 2007-11-15
US7632841B2 (en) 2009-12-15

Similar Documents

Publication Publication Date Title
AU2019394974B2 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
US20140248347A1 (en) Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
US20100081695A1 (en) 2-N-{5-[ [4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US8124640B2 (en) Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof
EP3733666B1 (en) Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof
KR101464053B1 (en) 4-methylpyrazole formulations
EP2937083A1 (en) Formulations, salts and polymorphs of transnorsertraline and uses thereof
US20090170893A1 (en) Novel hydrate form
EP1854794A1 (en) 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US8361971B2 (en) Tablet formulation of ezatiostat
CA2647829A1 (en) 2-n-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
JP7102200B2 (en) Solid pharmaceutical composition containing solifenacin succinate
HK1109773A (en) 2-n-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
HK1104557A (en) 2-n-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
KR20090006841A (en) 2-N-5-[[4- [2- (methyl-2-pyridinylamino) ethoxy] phenyl] methyl] -2,4-thiazolidinedionebutanedioic acid, preparation method thereof and maleic acid Compositions with Rosiglitazone
US20250339377A1 (en) Pharmaceutical composition of nucleoside-derived compound, preparation method therefor, and use thereof
US20160120825A1 (en) Stable crystal x-form agomelatine tablet and preparation method thereof
DE202006020710U1 (en) Compositions with rosiglitazone maleate
US20220267326A1 (en) Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
US20110021631A1 (en) Method of preparing stabilized pharmaceutical compositions comprising active ingredients susceptible to conversion to alternate polymorph forms
EP3470062A1 (en) Pharmaceutical tablet composition comprising bilastine and magnesium aluminometasilicate
CN119112863A (en) A dapagliflozin pharmaceutical composition and its preparation method and application
EP2301938A1 (en) Crystalline of eszopiclone, its composition, preparation and uses thereof
CN115569119A (en) Process for producing anamorelin tablets with improved stability
US7595335B2 (en) Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION